Skip to main content
NCBI home page
Clinical Cardiology logoLink to Clinical Cardiology
. 2009 May 19;32(8):E24–E30. doi: 10.1002/clc.20413

Twelve Months Clinical Outcome of Drug‐Eluting Stents Implantation or Coronary Artery Bypass Surgery for the Treatment of Diabetic Patients with Multivessel Disease

Yan Qiao 1, Changsheng Ma 1,✉, Shaoping Nie 1, Xiaohui Liu 1, Junping Kang 1, Qiang Lv 1, Xin Du 1, Rong Hu 1, Yin Zhang 1, Changqi Jia 1, Xinmin Liu 1, Jianzeng Dong 1, Fang Chen 1, Yujie Zhou 1, Shuzheng Lv 1, Fangjiong Huang 1, Chengxiong Gu 1, Xuesi Wu 1
PMCID: PMC6652847  PMID: 19455692

Abstract

Background

Studies comparing coronary artery bypass grafting (CABG) with drug‐eluting stent (DES) for the treatment of diabetic patients with multivessel disease are relatively scarce although controversies exist concerning the relative efficacy of CABG versus DES.

Hypothesis

The aim of this study was to evaluate the effect of drug‐eluting stent (DES) implantation in diabetic patients with multivessel disease compared with CABG.

Methods

We included 645 consecutive diabetic patients who underwent either CABG (n = 282) or DES implantation (n = 363) in our institution from July 2003 to December 2005.

Results

At 12 mo after index revascularization procedure, the total mortality rate was similar in the CABG and DES group (3.2% versus 3.0%, hazard ratio [HR] of CABG versus percutaneous coronary intervention [PCI] 0.58, 95% confidence interval [CI]: 0.14 to 2.45, p = 0.460), but the rate of major adverse cardiac cerebrovascular events was lower in the CABG group (7.8% versus 17.9%, HR: 0.15, 95% CI: 0.06 to 0.37, p < 0.001) mainly due to less repeat revascularization with CABG (1.4% versus 11.6%, HR: 0.02, 95% CI: 0.01 to 0.13, p < 0.001). Age, 3‐vessel disease, and serum creatinine ≥1.5 mg/dl were positive independent predictors of 12 mo death.

Conclusions

At 12 mo, CABG was associated with less adverse events primarily due to less repeat revascularization compared with DES although there was no significant difference in mortality and myocardial infarction (MI) rates between the 2 groups; high repeat revascularization rate related to DES resulted from high restenosis rate in diabetic patients and lower rate of complete revascularization offered by PCI. Copyright © 2009 Wiley Periodicals, Inc.

Full Text

The Full Text of this article is available as a PDF (150.1 KB).

References

  • 1. Braunwald E, Antman EM, Beasley JW, et al. ACC/AHA 2002 guideline update for the management of patients with unstable angina and non‐ST‐segment elevation myocardial infarction—summary article: A report of the American College of Cardiology/American Heart Association task force on practice guidelines (Committee on the management of patients with unstable angina). J Am Coll Cardiol 2002; 40: 1366–1374. [DOI] [PubMed] [Google Scholar]
  • 2. Antman EM, Anbe DT, Armstrong PW, et al. ACC/AHA guidelines for the management of patients with ST‐elevation myocardial infarction—executive summary. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing committee to revise the 1999 guidelines for the management of patients with acute myocardial infarction). J Am Coll Cardiol 2004; 44: 671–719. [DOI] [PubMed] [Google Scholar]
  • 3. Parsonnet VDD, Bernstein AD. A method of uniform stratification of risk for evaluating the results of surgery in acquired adult heart disease. Circulation 1989; 79(Suppl I):I 3–12. [PubMed] [Google Scholar]
  • 4. D'Agostino RB Jr, D'Agostino RB Sr. Estimating treatment effects using observational data. JAMA 2007; 297: 314–316. [DOI] [PubMed] [Google Scholar]
  • 5. The Bypass Angioplasty Revascularization Investigation (BARI) Investigators . Comparison of coronary bypass surgery with angioplasty in patients with multivessel disease. N Engl J Med 1996; 335: 217–225. [DOI] [PubMed] [Google Scholar]
  • 6. Hoffman SN, TenBrook JA, Wolf MP, et al. A meta‐analysis of randomized controlled trials comparing coronary artery bypass graft with percutaneous transluminal coronary angioplasty: one‐ to eight‐year outcomes. J Am Coll Cardiol 2003; 41: 1293–1304. [DOI] [PubMed] [Google Scholar]
  • 7. Serruys PW, Ong AT, van Herwerden LA, et al. Five‐year outcomes after coronary stenting versus bypass surgery for the treatment of multivessel disease: The final analysis of the Arterial Revascularization Therapies Study (ARTS) randomized trial. J Am Coll Cardiol 2005; 46: 575–581. [DOI] [PubMed] [Google Scholar]
  • 8. Hermiller JB, Raizner A, Cannon L, et al. Outcomes with the polymer‐based paclitaxel‐eluting TAXUS stent in patients with diabetes mellitus: The TAXUS‐IV trial. J Am Coll Cardiol 2005; 45: 1172–1179. [DOI] [PubMed] [Google Scholar]
  • 9. Sabate M, Jimenez‐Quevedo P, Angiolillo DJ, et al. Randomized comparison of sirolimus‐eluting stent versus standard stent for percutaneous coronary revascularization in diabetic patients: The diabetes and sirolimus‐eluting stent (DIABETES) trial. Circulation 2005; 112: 2175–2183. [DOI] [PubMed] [Google Scholar]
  • 10. Macaya C, Garcia H, Serruys PW. Sirolimus‐eluting stent versus surgery and bare metal stenting in the treatment of diabetic patients with multivessel disease—a comparison between ARTS II and ARTS I. Circulation 2005; 112(suppl II): II–655. [Google Scholar]
  • 11. Hannan EL, Wu C, Walford G, et al. Drug‐eluting stents versus coronary‐artery bypass grafting in multivessel coronary disease. N Engl J Med 2008; 358: 331–341. [DOI] [PubMed] [Google Scholar]
  • 12. Holmes DR Jr, Leon MB, Moses JW, et al. Analysis of 1‐year clinical outcomes in the SIRIUS trial: A randomized trial of a sirolimus‐eluting stent versus a standard stent in patients at high risk for coronary restenosis. Circulation 2004; 109: 634–640. [DOI] [PubMed] [Google Scholar]
  • 13. Dibra A, Kastrati A, Mehilli J, et al. Paclitaxel‐eluting or sirolimus‐eluting stents to prevent restenosis in diabetic patients. N Engl J Med 2005; 353: 663–670. [DOI] [PubMed] [Google Scholar]
  • 14. Costa MA, Simon DI. Molecular basis of restenosis and drug‐eluting stents. Circulation 2005; 111: 2257–2273. [DOI] [PubMed] [Google Scholar]
  • 15. van den Brand MJ, Rensing BJ, Morel MA, et al. The effect of completeness of revascularization on event‐free survival at one year in the ARTS trial. J Am Coll Cardiol 2002; 39: 559–564. [DOI] [PubMed] [Google Scholar]
  • 16. McLellan CS, Ghali WA, Labinaz M, et al. Association between completeness of percutaneous coronary revascularization and postprocedure outcomes. Am Heart J 2005; 150: 800–806. [DOI] [PubMed] [Google Scholar]
  • 17. Nesto RW, Phillips RT, Kett KG, et al. Angina and exertional myocardial ischemia in diabetic and nondiabetic patients: Assessment by exercise thallium scintigraphy. Ann Intern Med 1988; 108: 170–175. [DOI] [PubMed] [Google Scholar]
  • 18. Briguori C, Condorelli G, Airoldi F, et al. Comparison of coronary drug‐eluting stents versus coronary artery bypass grafting in patients with diabetes mellitus. Am J Cardiol 2007; 99: 779–784. [DOI] [PubMed] [Google Scholar]

Articles from Clinical Cardiology are provided here courtesy of Wiley

RESOURCES